LA Private

December 2024

Salesforce surges 10% on Q3 results and AI progress

Shares in Salesforce (NYSE: CRM) surged more than 10% in after-hours trading following the release of the company’s fiscal Q3 2025 earnings report. The company exceeded revenue expectations, raised its full-year revenue outlook, and highlighted advancements in its artificial intelligence (AI) initiatives. Shares are currently trading at US$366.30, up from US$331.76 at Tuesday’s close. Salesforce […]

Salesforce surges 10% on Q3 results and AI progress Read More »

A Bravura performance: Upgraded FY25 guidance and dividend resumption

Bravura Solutions (ASX:BVS) has upgraded its financial guidance for FY25, reflecting strong performance and the successful execution of its strategic transformation over the past 18 months. The company also announced plans to recommence dividend payments, signalling a return to profitability and robust cash generation. The upgraded guidance includes: Cash EBITDA of $33m to $36m, up

A Bravura performance: Upgraded FY25 guidance and dividend resumption Read More »

Australian economy slows to 0.3% growth in September quarter

The Australian Bureau of Statistics (ABS) released economic data today. Here’s some of the key figures. Growth Australia’s economy grew by 0.3% in the September quarter 2024, marking the slowest annual growth rate since late 2020. This compares to a 0.8% growth rate in September 2023. Year-on-year, gross domestic product (GDP) rose 0.8%, continuing a pattern

Australian economy slows to 0.3% growth in September quarter Read More »

Alterity completes Phase 2 trial in multiple system atrophy

Alterity Therapeutics (ASX:ATH) has announced the completion of the Phase 2 clinical trial in multiple system atrophy (MSA) for its lead drug candidate, ATH434. No results were released, but Alterity plans to release topline results in late January or early February 2025. “We are very excited to announce that the last participant in our Phase 2 study

Alterity completes Phase 2 trial in multiple system atrophy Read More »

China’s ban on gallium, germanium and antimony exports sparks concern

China has announced an export ban to the United States on critical minerals gallium, germanium, and antimony, all of which hold significant military and technological applications. This move marks the latest escalation in trade tensions between the two global superpowers following Washington’s crackdown on China’s semiconductor industry. The Chinese Ministry of Commerce cited national security

China’s ban on gallium, germanium and antimony exports sparks concern Read More »

COSOL boosts analytics with $22m Toustone acquisition

COSOL (ASX:COS) has announced the acquisition of Toustone Pty Ltd, an Australian data analytics firm, for up to $22.4m. The acquisition aligns with COSOL’s strategy to expand its asset management solutions and enhance data analytics capabilities, particularly in sectors such as transport, agriculture and infrastructure. COSOL helps organisations in industries such as natural resources, infrastructure

COSOL boosts analytics with $22m Toustone acquisition Read More »

BlackRock to acquire HPS Investment Partners for US$12bn

BlackRock, the world’s largest asset manager, has agreed to acquire HPS Investment Partners for US$12bn in an all-stock deal, accelerating its expansion into private credit markets. The acquisition, announced Tuesday, highlights CEO Larry Fink’s strategy to diversify the firm’s offerings beyond traditional equities and bonds. HPS, a New York-based private credit manager overseeing US$148bn in

BlackRock to acquire HPS Investment Partners for US$12bn Read More »